Inventor · disambiguated record
Mark G. Erlander
Also filed as: ERLANDER MARK · ERLANDER MARK G
58 granted patents·75 pending applications·943 citations·filing 1990–2025
99Inventor score
Files withBIOTHERANOSTICS INC24CARDIFF ONCOLOGY INC15LIFE TECHNOLOGIES CORP12ORTHO MCNEIL PHARM INC11ERLANDER MARK G10
Top patents by PatentIndex Score
133 records- 0194US7504214B2Predicting outcome with tamoxifen in breast cancerBIOTHERANOSTICS INC·Filed 2003·Granted Mar 17, 2009·105 cites·43 claims
- 0293US7930105B2Grading of breast cancerBIOTHERANOSTICS INC·Filed 2007·Granted Apr 19, 2011·10 cites·20 claims
- 0393US6794141B2Nucleic acid amplificationARCTURUS BIOSCIENCE INC·Filed 2001·Granted Sep 21, 2004·49 cites·32 claims
- 0492US7723039B2Gene expression profiling from FFPE samplesMDS ANALYTICAL TECHNOLOGIES US·Filed 2008·Granted May 25, 2010·10 cites·19 claims
- 0591US8012688B2Gene expression profiling from FFPE samplesLIFE TECHNOLOGIES CORP·Filed 2010·Granted Sep 6, 2011·5 cites·36 claims
- 0691US7364846B2Gene expression profiling from FFPE samplesMOLECULAR DEVICES CORP·Filed 2002·Granted Apr 29, 2008·19 cites·23 claims
- 0790US7879555B2Gene expression profiling from FFPE samplesLIFE TECHNOLOGIES CORP·Filed 2009·Granted Feb 1, 2011·5 cites·18 claims
- 0889US9447470B2Tumor grading and cancer prognosisERLANDER MARK G·Filed 2010·Granted Sep 20, 2016·8 cites·9 claims
- 0989US5846740AMethods and kits useful for detecting autoantibody to glutamic acid decarboxylaseUNIV CALIFORNIA·Filed 1995·Granted Dec 8, 1998·80 cites·8 claims
- 1088US10329624B2Grading of breast cancerBIOTHERANOSTICS INC·Filed 2016·Granted Jun 25, 2019·2 cites·16 claims
- 1188US9670553B2Determining tumor originBIOTHERANOSTICS INC·Filed 2015·Granted Jun 6, 2017·3 cites·15 claims
- 1288US5459037AMethod for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrationsSCRIPPS RESEARCH INST·Filed 1993·Granted Oct 17, 1995·81 cites·4 claims
- 1387US5998366AMethod for ameliorating glutamic acid decarboxylase associated autoimmune disordersUNIV CALIFORNIA·Filed 1997·Granted Dec 7, 1999·63 cites·36 claims
- 1486US6682906B1Cloned glutamic acid decarboxylaseUNIV CALIFORNIA·Filed 1990·Granted Jan 27, 2004·44 cites·18 claims
- 1585US9725755B2Synthesis and enrichment of nucleic acid sequencesTROVAGENE INC·Filed 2016·Granted Aug 8, 2017·17 cites·20 claims
- 1685US6855560B1Method of identifying compounds that modulate human histamine H3 receptorORTHO MCNEIL PHARM INC·Filed 2000·Granted Feb 15, 2005·7 cites·8 claims
- 1784US12263173B2PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancerCARDIFF ONCOLOGY INC·Filed 2024·Granted Apr 1, 2025·0 cites·20 claims
- 1884US12144813B2PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancerCARDIFF ONCOLOGY INC·Filed 2024·Granted Nov 19, 2024·0 cites·16 claims
- 1983US10036060B2Nucleic acid amplificationLIFE TECHNOLOGIES CORP·Filed 2014·Granted Jul 31, 2018·1 cites·14 claims
- 2083US6455267B1Methods and kits useful for determining the status of and detecting pancreatic B-cell associated autoimmune diseasesUNIV CALIFORNIA·Filed 1995·Granted Sep 24, 2002·43 cites·13 claims
- 2183US6136559ADNA encoding as human histamine receptor of the H3 subtypeORTHO PHARMA CORP·Filed 1998·Granted Oct 24, 2000·28 cites·4 claims
- 2283US6011139AHybridomas and monoclonal antibodies that specifically bind to glutamic acid decarboxylase peptidesUNIV CALIFORNIA·Filed 1995·Granted Jan 4, 2000·43 cites·20 claims
- 2383US2025101092A1Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancerCARDIFF ONCOLOGY INC·Filed 2024·Application pending·0 cites
- 2482US5674978APeptides derived from glutamic acid decarboxylaseUNIV CALIFORNIA·Filed 1993·Granted Oct 7, 1997·49 cites·8 claims
- 2581US11430544B2Identification of tumors and tissuesBIOTHERANOSTICS INC·Filed 2016·Granted Aug 30, 2022·1 cites·8 claims
- 2681US6437100B1DNA encoding a human histamine receptor of the H3 subtypeORTHO PHARMA CORP·Filed 2000·Granted Aug 20, 2002·4 cites·2 claims
- 2781US6413743B1DNA encoding a human histamine receptor of the H3 subtypeORTHO PHARMA CORP·Filed 2000·Granted Jul 2, 2002·4 cites·4 claims
- 2881US6277586B1Cloned glutamic acid decarboxylaseUNIV CALIFORNIA·Filed 1999·Granted Aug 21, 2001·38 cites·6 claims
- 2980US10538816B2Identification of tumorsBIOTHERANOSTICS INC·Filed 2016·Granted Jan 21, 2020·1 cites·20 claims
- 3080US2025057847A1Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancerCARDIFF ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 3179US5705626ACloned glutamic acid decarboxylase nucleic acidsUNIV CALIFORNIA·Filed 1995·Granted Jan 6, 1998·44 cites·6 claims
- 3279US2023023867A1Identification of tumors and tissuesBIOTHERANOSTICS INC·Filed 2022·Application pending·0 cites
- 3377US5475086ACloned glutamic acid decarboxylase peptidesUNIV CALIFORNIA·Filed 1993·Granted Dec 12, 1995·43 cites·3 claims
- 3476US6455278B1DNA encoding human vanilloid receptor VR3ORTHO MCNEIL PHARM INC·Filed 2000·Granted Sep 24, 2002·7 cites·9 claims
- 3576US2015152478A1Gene expression profiling from ffpe samplesLIFE TECHNOLOGIES CORP·Filed 2014·Application pending·0 cites
- 3675US6107476ANucleic acid molecule encoding a protein growth factor for inhibiting prostate cancer cell growthORTHO MCNEIL PHARM INC·Filed 1997·Granted Aug 22, 2000·24 cites·1 claims
- 3775US5807680AMethod for simulataneous identification of differentially expresed mRNAS and measurement of relative concentrationsSCRIPPS RESEARCH INST·Filed 1995·Granted Sep 15, 1998·35 cites·33 claims
- 3875US2020362393A1Gene expression profiling from ffpe samplesLIFE TECHNOLOGIES CORP·Filed 2020·Application pending·0 cites
- 3975US2025223348A1Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancerCARDIFF ONCOLOGY INC·Filed 2025·Application pending·0 cites
- 4075US2020190597A1Identification of tumorsBIOTHERANOSTICS INC·Filed 2019·Application pending·0 cites
- 4174US8435739B2Gene expression profiling from FFPE samplesERLANDER MARK G·Filed 2012·Granted May 7, 2013·0 cites·20 claims
- 4274US2020095642A1Grading of breast cancerBIOTHERANOSTICS INC·Filed 2019·Application pending·0 cites
- 4373US12492432B2Tumor grading and cancer prognosisBIOTHERANOSTICS INC·Filed 2021·Granted Dec 9, 2025·0 cites·19 claims
- 4473US9856533B2Predicting breast cancer treatment outcomeERLANDER MARK G·Filed 2004·Granted Jan 2, 2018·2 cites·9 claims
- 4573US7179604B2Methods of use of DNA encoding a human histamine receptor of the H3 subtypeORTHO MCNEIL PHARM INC·Filed 2003·Granted Feb 20, 2007·1 cites·13 claims
- 4673US6596484B1Method for simultaneous sequence-specific identification and display of mRNA'sSCRIPPS RESEARCH INST·Filed 2000·Granted Jul 22, 2003·2 cites·37 claims
- 4773US2019002957A1Nucleic acid amplificationLIFE TECHNOLOGIES CORP·Filed 2018·Application pending·0 cites
- 4873US2021062244A1Nucleic acid amplificationLIFE TECHNOLOGIES CORP·Filed 2020·Application pending·0 cites
- 4972US12460265B2Post-treatment breast cancer prognosisBIOTHERANOSTICS INC·Filed 2021·Granted Nov 4, 2025·0 cites·11 claims
- 5072US7186803B2Human vanilloid receptor VR3 proteinORTHO MCNEIL PHARM INC·Filed 2004·Granted Mar 6, 2007·4 cites·2 claims
Showing the top 50 of 133 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Mark G. Erlander files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →